TB-500 side effects, separated by evidence tier: what the human thymosin β4 trials actually recorded, what uncontrolled self-report adds, and the gaps neither covers.
Search volume for "TB-500 side effects" implies a settled adverse-event profile exists. It does not. What exists is a small set of human trials of a related molecule, given by routes almost nobody uses outside a clinic, plus a large volume of uncontrolled self-report. This page keeps those tiers separate, because the distinction is the whole story.
Thymosin β4 (Tβ4) is a 43-amino-acid actin-sequestering peptide found in most human cells. "TB-500" is a research-market label, most often applied to a short synthetic fragment corresponding to the actin-binding region around residues 17–23 (the Ac-LKKTETQ motif), though some material sold under the name is full-length Tβ4 instead. The two are not pharmacologically interchangeable: they differ in molecular weight, in clearance, and plausibly in which of Tβ4's several activities they retain.
Nearly every human safety dataset cited in TB-500 marketing was generated with full-length Tβ4. Carrying those tolerability numbers across to a heptapeptide fragment is an inference, not a finding. Our TB-500 research overview covers the mechanistic side of that gap in more detail.
Intravenous, healthy volunteers. Ruff and colleagues published a randomized, placebo-controlled single- and multiple-ascending-dose Phase I study of synthetic Tβ4 in the Annals of the New York Academy of Sciences (2010). Cohorts of ten received single intravenous doses of 42, 140, 420, or 1,260 mg, then the same regimen daily for 14 days. Adverse events were infrequent and mild to moderate; the most frequent in the multiple-dose portion were headache and upper respiratory infection. No dose-limiting toxicities and no serious adverse events were recorded across that range.
Intravenous, recombinant. A 2021 first-in-human study of recombinant human Tβ4 (published in the Journal of Cellular and Molecular Medicine) ran single ascending doses from 0.05 to 25 µg/kg in 54 volunteers and multiple doses of 0.5, 2.0, and 5.0 µg/kg daily for 10 days in 30 more. Adverse events were again mild to moderate and self-resolving, with incidence numerically higher in the placebo arms than the treated arms in both phases — the pattern you expect when background symptom reporting dominates. Laboratory findings included transient biochemistry, urinalysis, and tumour-marker abnormalities, among them squamous cell carcinoma antigen elevations the authors attributed to epithelial regeneration.
Note the dose gulf between those two programmes — milligrams versus micrograms per kilogram, a difference of roughly three orders of magnitude. That alone should discourage anyone from reading a single "tolerated range" off the literature.
Topical and ophthalmic. A Phase II venous stasis ulcer trial (NCT00832091, RegeneRx) randomized 72 patients to Tβ4 gel at 0.01%, 0.03%, or 0.1% w/w or placebo, once daily for up to 84 days. Posted results list serious events in both placebo and active arms in small numbers — connective-tissue inflammation, skin ulcer, lymphangitis, a transaminase elevation — alongside non-serious events dominated by laboratory abnormalities and infections expected in a chronic-wound population. The trial was not powered to detect a safety signal. A separate Phase II dry-eye study of 0.1% Tβ4 ophthalmic solution over 28 days reported no adverse events among enrolled subjects.
Everything most purchasers care about. There is no controlled human safety data for:
The published record supports a narrow claim — full-length Tβ4 was well tolerated in short IV and topical courses in small trials — and nothing broader.
Community and vendor sources describe injection-site erythema, swelling, and tenderness, and transient fatigue or lethargy in the first days of use. These are uncontrolled, unblinded self-reports with no denominator; they cannot establish incidence, causation, or severity. Treat them as hypotheses, not findings.
Tβ4 promotes endothelial cell migration and angiogenesis — the property that makes it interesting for wound and cardiac repair. Angiogenesis also supports tumour growth, which is why the theoretical oncological concern is raised repeatedly. Standard preclinical work has not demonstrated tumour promotion, but no human study has been designed, sized, or run long enough to detect a malignancy signal. "No signal found" and "looked for and not found" are different statements, and only the first is true here.
Some share of reported reactions in unregulated peptide use plausibly traces to the vial rather than the molecule: synthesis impurities, residual solvents, endotoxin load, or material degraded by a broken cold chain. Third-party analysis is the only way to separate compound effects from product effects — see reading a peptide Certificate of Analysis.
No thymosin β4 product is approved for human use in the United States or Canada. Thymosin-β4 and its derivatives, TB-500 explicitly named, were added as examples of prohibited growth factors under section S2.3 of the WADA Prohibited List effective with the 2018 edition; athletes should verify the current List directly.
Does TB-500 have a documented side-effect profile? Not in the sense the question implies. Full-length thymosin β4 has short-course human tolerability data from small Phase I and Phase II trials. The fragment marketed as TB-500, given subcutaneously and repeatedly, has none.
What adverse events appeared in the Phase I intravenous trial? Ruff et al. (2010) reported infrequent, mild-to-moderate events across 42–1,260 mg doses, headache and upper respiratory infection being most common in the multiple-dose portion, with no dose-limiting toxicities or serious adverse events.
Is the cancer concern established? No, and neither is its absence. Tβ4 is pro-angiogenic, which motivates the theoretical concern; preclinical studies have not shown tumour promotion, and no human trial has been long or large enough to test the question.
Why do the two intravenous trials use such different doses? They used different preparations — synthetic versus recombinant — and different dosing frameworks, one in absolute milligrams and one per kilogram. The roughly thousand-fold gap is a reason to treat any single published figure as non-transferable.
Are TB-500 and BPC-157 studied together? They are frequently combined in practice, including in blended products, but there is no controlled human safety data on the combination. Interaction effects are unstudied.
